New Delhi: TheRona virus vaccines Covisheild and Covaxin are expected to get regular market approval from India's drug regulator soon. After this, each dose is likely to be fixed at Rs 275 and the additional service charge at Rs 150. According to him, the National Pharmaceutical Pricing Authority (NPPA) has been directed to start working towards limiting prices to make the vaccine affordable.
As of now, Covaxin is priced at Rs 1,200 per dose, while Covishield is priced at Rs 780. A service charge of Rs 150 has also been added to the prices. Both vaccines are authorized for emergency use only in the country. On January 19, the Subject Expert Committee of the Central Drugs Standard Control Organisation on coronavirus had recommended regular market approval for corona vaccines - Covishield and Covaxin - for use in the adult population subject to certain conditions.
Prakash Kumar Singh, director (government and regulatory affairs) of serum institute of India, had submitted an application to the Drugs Controller General of India on October 25, seeking regular market approval for the Covisheild vaccine.
L&T inks MoU with HydrogenPro to produce hydrogen electrolysers in India
